IL161921A0 - 3-Cyanoquinolines as inhibitors of egf-r and her2 kinases - Google Patents

3-Cyanoquinolines as inhibitors of egf-r and her2 kinases

Info

Publication number
IL161921A0
IL161921A0 IL16192102A IL16192102A IL161921A0 IL 161921 A0 IL161921 A0 IL 161921A0 IL 16192102 A IL16192102 A IL 16192102A IL 16192102 A IL16192102 A IL 16192102A IL 161921 A0 IL161921 A0 IL 161921A0
Authority
IL
Israel
Prior art keywords
cyanoquinolines
egf
inhibitors
her2 kinases
her2
Prior art date
Application number
IL16192102A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of IL161921A0 publication Critical patent/IL161921A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16192102A 2001-11-27 2002-11-26 3-Cyanoquinolines as inhibitors of egf-r and her2 kinases IL161921A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33356801P 2001-11-27 2001-11-27
PCT/US2002/037918 WO2003050090A1 (en) 2001-11-27 2002-11-26 3-cyanoquinolines as inhibitors of egf-r and her2 kinases

Publications (1)

Publication Number Publication Date
IL161921A0 true IL161921A0 (en) 2005-11-20

Family

ID=23303345

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16192102A IL161921A0 (en) 2001-11-27 2002-11-26 3-Cyanoquinolines as inhibitors of egf-r and her2 kinases

Country Status (24)

Country Link
US (1) US6821988B2 (uk)
EP (1) EP1448531B1 (uk)
JP (1) JP2005514384A (uk)
KR (1) KR20050044599A (uk)
CN (1) CN1659145A (uk)
AR (1) AR037438A1 (uk)
AT (1) ATE370123T1 (uk)
AU (1) AU2002359489B2 (uk)
BR (1) BR0214485A (uk)
CA (1) CA2467573A1 (uk)
CO (1) CO5580828A2 (uk)
DE (1) DE60221886D1 (uk)
EC (1) ECSP045122A (uk)
HU (1) HUP0402228A2 (uk)
IL (1) IL161921A0 (uk)
MX (1) MXPA04004969A (uk)
NO (1) NO20042634L (uk)
NZ (1) NZ533118A (uk)
PL (1) PL370137A1 (uk)
RU (1) RU2309150C2 (uk)
TW (1) TW200300348A (uk)
UA (1) UA77469C2 (uk)
WO (1) WO2003050090A1 (uk)
ZA (1) ZA200405025B (uk)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
EP2280003B1 (en) * 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
MXPA06001110A (es) * 2003-08-01 2006-04-11 Wyeth Corp Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer.
BR0318503A (pt) * 2003-09-15 2006-09-12 Wyeth Corp quinolinas substituìdas como inibidores de enzima proteìna tirosina cinase
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
US7365203B2 (en) * 2003-09-15 2008-04-29 Wyeth Process for the synthesis of 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-ethoxy-quinoline-3-carbonitrile
SI2392564T1 (sl) * 2003-09-26 2014-02-28 Exelixis, Inc. c-Met modulatorji in postopki uporabe
US7781591B2 (en) 2006-06-13 2010-08-24 Wyeth Llc Substituted 3-cyanopyridines as protein kinase inhibitors
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
US7410988B2 (en) 2004-08-13 2008-08-12 Genentech, Inc. 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
TW200616612A (en) * 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention
CN102886045A (zh) 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
US7624279B2 (en) * 2005-06-29 2009-11-24 Lenovo Singapore Pte. Ltd. System and method for secure O.S. boot from password-protected HDD
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
EP1942937A1 (en) 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
RU2448708C3 (ru) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
ES2558706T3 (es) * 2006-06-13 2016-02-08 Wyeth Llc 3-cianopiridinas sustituidas como inhibidores de proteína cinasa
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009060945A1 (ja) 2007-11-09 2009-05-14 Eisai R & D Management Co., Ltd. 血管新生阻害物質と抗腫瘍性白金錯体との併用
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
PL2310011T3 (pl) 2008-06-17 2013-12-31 Wyeth Llc Kombinacje przeciwnowotworowe zawierające HKI-272 i vinorelbine
SG10202102855RA (en) 2008-08-04 2021-05-28 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
ITMI20082336A1 (it) * 2008-12-29 2010-06-30 Univ Parma Composti inibitori irreversibili di egfr con attivita' antiproliferativa
CA2995880C (en) 2009-01-16 2021-01-05 Exelixis, Inc. Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
MX356593B (es) 2009-04-06 2018-06-05 Wyeth Llc Régimen de tratamiento que utiliza neratinib para cáncer de mama.
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CN107308130B (zh) 2009-11-09 2021-06-15 惠氏有限责任公司 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途
AU2011264209B2 (en) * 2010-06-09 2014-08-07 Tianjin Hemay Oncology Pharmaceutical Co., Ltd Cyanoquinoline derivatives
BR112012032462A2 (pt) 2010-06-25 2016-11-08 Eisai R&D Man Co Ltd agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
WO2012027537A1 (en) * 2010-08-26 2012-03-01 Symphony Evolution, Inc. Use of a receptor-type kinase modulator for treating polycystic kidney disease
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CN104755463A (zh) 2012-12-21 2015-07-01 卫材R&D管理有限公司 非晶态形式的喹啉衍生物及其生产方法
CN103214489B (zh) * 2013-02-25 2016-10-26 中国人民解放军第二军医大学 一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法
MX368099B (es) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
CN103304494B (zh) * 2013-06-20 2015-05-27 河北大学 茚(1,2-b)喹喔啉-11-酮肟衍生物及其制备方法和用途
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
BR112017017428A2 (pt) 2015-02-25 2018-04-03 Eisai R&D Management Co., Ltd. ?método para supressão do amargor de derivado de quinolina?
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
WO2016210345A1 (en) 2015-06-25 2016-12-29 The California Institute For Biomedical Research Composition and methods for inhibiting mammalian sterile 20-like kinase 1
WO2017117474A1 (en) * 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional compounds for her3 degradation and methods of use
WO2017148391A1 (zh) * 2016-03-01 2017-09-08 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
DK3658552T3 (da) 2017-07-28 2023-11-20 Yuhan Corp Fremgangsmåde til fremstilling af n-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamid ved reaktion af den tilsvarende amin med et 3-halogen-propionylchlorid
CN110452232A (zh) * 2019-09-17 2019-11-15 北京振东光明药物研究院有限公司 阿法替尼杂质化合物及其制备方法与应用
CN111995618B (zh) * 2020-09-02 2021-06-11 重庆医科大学 一种来那替尼杂质g的制备方法
CN111943933B (zh) * 2020-09-02 2021-05-28 重庆医科大学 一种来那替尼杂质d的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125686A (en) * 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235740B1 (en) * 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
BR9914164A (pt) * 1998-09-29 2001-06-26 American Cyanamid Co Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto
UA72749C2 (en) 1998-09-29 2005-04-15 White Holdings Corp Substituted 3-cyanoquinolines, a method for the preparation thereof (variants), pharmaceutical composition based thereon, a method for the treatment, inhibiting the growth or elimination of neoplasms and a method for the treatment, inhibiting progressing or elimination of polycystic kidney disease using them
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
JP2003519127A (ja) * 1999-12-29 2003-06-17 ワイス 三環系タンパクキナーゼ阻害薬
EP1337524A1 (en) 2000-11-02 2003-08-27 AstraZeneca AB Substituted quinolines as antitumor agents

Also Published As

Publication number Publication date
AU2002359489A1 (en) 2003-06-23
ZA200405025B (en) 2006-12-27
HUP0402228A2 (hu) 2005-02-28
TW200300348A (en) 2003-06-01
NO20042634L (no) 2004-06-23
JP2005514384A (ja) 2005-05-19
CN1659145A (zh) 2005-08-24
UA77469C2 (en) 2006-12-15
AU2002359489B2 (en) 2008-10-30
AR037438A1 (es) 2004-11-10
BR0214485A (pt) 2004-09-14
DE60221886D1 (de) 2007-09-27
KR20050044599A (ko) 2005-05-12
CO5580828A2 (es) 2005-11-30
EP1448531B1 (en) 2007-08-15
US20030149056A1 (en) 2003-08-07
US6821988B2 (en) 2004-11-23
ATE370123T1 (de) 2007-09-15
ECSP045122A (es) 2004-07-23
RU2309150C2 (ru) 2007-10-27
CA2467573A1 (en) 2003-06-19
MXPA04004969A (es) 2004-08-11
EP1448531A1 (en) 2004-08-25
RU2004119414A (ru) 2006-02-27
WO2003050090A1 (en) 2003-06-19
NZ533118A (en) 2006-07-28
PL370137A1 (en) 2005-05-16

Similar Documents

Publication Publication Date Title
IL161921A0 (en) 3-Cyanoquinolines as inhibitors of egf-r and her2 kinases
HK1160859A1 (en) Inhibitors of tyrosine kinases
IL161576A0 (en) Benzimidazoles and analogues and their use as protein kinases inhibitors
EP1363702A4 (en) PROCESS FOR INHIBITING KINASES
HK1053832A1 (zh) 蛋白激酶抑制劑
MXPA03006420A (es) Diaminotiazoles.
PT1562589E (pt) Diaminotriazoles úteis como inibidores de proteína-quinases
HK1076598A1 (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
PL375389A1 (en) Novel inhibitors of kinases
HK1061854A1 (en) Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
AU2003256297A1 (en) Benzimidazoles and benzothiazoles as inhibitors of map kinase
AU2002308748A1 (en) Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
AU2003282891A8 (en) Novel tyrosine kinases inhibitors
EP1372654A4 (en) QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES
PL369742A1 (en) Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
MXPA03009257A (es) Derivados de isoxaxol como inhibidores de src y otras proteinas cinasas.
EP1424897A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
MXPA03006423A (es) Naftostirilos.
AU2002306845A1 (en) Telomerase inhibitors and methods of their use
ZA200305379B (en) Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase.
AU2002303336A1 (en) Isoxaxole derivatives as inhibitors of src and other protein kinases
AU2002317319A1 (en) Quinoline derivatives and their use as tyrosine kinase inhibitors